Session

Eosinophilic oesophagitis (Posters)

NOVEL ROBUST METHOD FOR EOSINOPHIL COUNTING IN DUODENAL BIOPSY SECTIONS
NOVEL ROBUST METHOD FOR EOSINOPHIL COUNTING IN DUODENAL BIOPSY SECTIONS

DUPILUMAB FOR THE TREATMENT OF EOSINOPHILIC ESOPHAGITIS: A MULTICENTER REAL-LIFE EXPERIENCE
DUPILUMAB FOR THE TREATMENT OF EOSINOPHILIC ESOPHAGITIS: A MULTICENTER REAL-LIFE EXPERIENCE

DIFFERENCES IN TREATMENT PATTERNS AMONG PATIENTS DIAGNOSED WITH EOSINOPHILIC OESOPHAGITIS IN THE UNITED STATES
DIFFERENCES IN TREATMENT PATTERNS AMONG PATIENTS DIAGNOSED WITH EOSINOPHILIC OESOPHAGITIS IN THE UNITED STATES

INHIBITORY EFFECT OF PHARMACOLOGICALLY-DERIVED OR ENDOGENOUSLY PRODUCED HYDROGEN SULFIDE (H2S) ON THE DEVELOPMENT OF BARRETT’S METAPLASIA THROUGH IL-1BETA/COX-2/PGE2 PATHWAY LOOP
INHIBITORY EFFECT OF PHARMACOLOGICALLY-DERIVED OR ENDOGENOUSLY PRODUCED HYDROGEN SULFIDE (H2S) ON THE DEVELOPMENT OF BARRETT’S METAPLASIA THROUGH IL-1BETA/COX-2/PGE2 PATHWAY LOOP

CHANGING STRATEGY FOR BARRETT’S SURVEILLANCE: USINGCYTOSPONGE AND GASTROSCOPY OVER 14 MONTHS DURING COVID19
CHANGING STRATEGY FOR BARRETT’S SURVEILLANCE: USINGCYTOSPONGE AND GASTROSCOPY OVER 14 MONTHS DURING COVID19

DEVELOPMENT OF THE EOSINOPHILIC ESOPHAGITIS DAILY DYSPHAGIA DIARY, A PATIENT REPORTED OUTCOME ASSESSMENT TO MEASURE FREQUENCY AND SEVERITY OF DYSPHAGIA EPISODES IN EOSINOPHILIC ESOPHAGITIS
DEVELOPMENT OF THE EOSINOPHILIC ESOPHAGITIS DAILY DYSPHAGIA DIARY, A PATIENT REPORTED OUTCOME ASSESSMENT TO MEASURE FREQUENCY AND SEVERITY OF DYSPHAGIA EPISODES IN EOSINOPHILIC ESOPHAGITIS

OPTIMAL PROCEDURAL TIME ENSURES ADHERENCE TO SEATTLE PROTOCOL AND MAXIMIZES DYSPLASIA DETECTION IN BARRETT’S ESOPHAGUS SURVEILLANCE
OPTIMAL PROCEDURAL TIME ENSURES ADHERENCE TO SEATTLE PROTOCOL AND MAXIMIZES DYSPLASIA DETECTION IN BARRETT’S ESOPHAGUS SURVEILLANCE

PHYSICIAN-DOCUMENTED SYMPTOMS AND TREATMENT AMONG PATIENTS WITH EOSINOPHILIC ESOPHAGITIS IN FIVE EUROPEAN COUNTRIES: EVIDENCE FROM REAL-WORLD CLINICAL PRACTICE
PHYSICIAN-DOCUMENTED SYMPTOMS AND TREATMENT AMONG PATIENTS WITH EOSINOPHILIC ESOPHAGITIS IN FIVE EUROPEAN COUNTRIES: EVIDENCE FROM REAL-WORLD CLINICAL PRACTICE

PATIENT-REPORTED SYMPTOMS OF EOSINOPHILIC ESOPHAGITIS IN FIVE EUROPEAN COUNTRIES: EVIDENCE FROM REAL-WORLD CLINICAL PRACTICE
PATIENT-REPORTED SYMPTOMS OF EOSINOPHILIC ESOPHAGITIS IN FIVE EUROPEAN COUNTRIES: EVIDENCE FROM REAL-WORLD CLINICAL PRACTICE

PATIENT-REPORTED SYMPTOMS OF EOSINOPHILIC ESOPHAGITIS IN FIVE EUROPEAN COUNTRIES: EVIDENCE FROM REAL-WORLD CLINICAL PRACTICE
PATIENT-REPORTED SYMPTOMS OF EOSINOPHILIC ESOPHAGITIS IN FIVE EUROPEAN COUNTRIES: EVIDENCE FROM REAL-WORLD CLINICAL PRACTICE

Eosinophilic oesophagitis (Posters)  et al.

PHYSICIAN-DOCUMENTED SYMPTOMS AND TREATMENT AMONG PATIENTS WITH EOSINOPHILIC ESOPHAGITIS IN FIVE EUROPEAN COUNTRIES: EVIDENCE FROM REAL-WORLD CLINICAL PRACTICE
PHYSICIAN-DOCUMENTED SYMPTOMS AND TREATMENT AMONG PATIENTS WITH EOSINOPHILIC ESOPHAGITIS IN FIVE EUROPEAN COUNTRIES: EVIDENCE FROM REAL-WORLD CLINICAL PRACTICE

Eosinophilic oesophagitis (Posters)  et al.

OPTIMAL PROCEDURAL TIME ENSURES ADHERENCE TO SEATTLE PROTOCOL AND MAXIMIZES DYSPLASIA DETECTION IN BARRETT’S ESOPHAGUS SURVEILLANCE
OPTIMAL PROCEDURAL TIME ENSURES ADHERENCE TO SEATTLE PROTOCOL AND MAXIMIZES DYSPLASIA DETECTION IN BARRETT’S ESOPHAGUS SURVEILLANCE

Eosinophilic oesophagitis (Posters)  et al.

DEVELOPMENT OF THE EOSINOPHILIC ESOPHAGITIS DAILY DYSPHAGIA DIARY, A PATIENT REPORTED OUTCOME ASSESSMENT TO MEASURE FREQUENCY AND SEVERITY OF DYSPHAGIA EPISODES IN EOSINOPHILIC ESOPHAGITIS
DEVELOPMENT OF THE EOSINOPHILIC ESOPHAGITIS DAILY DYSPHAGIA DIARY, A PATIENT REPORTED OUTCOME ASSESSMENT TO MEASURE FREQUENCY AND SEVERITY OF DYSPHAGIA EPISODES IN EOSINOPHILIC ESOPHAGITIS

Eosinophilic oesophagitis (Posters)  et al.

CHANGING STRATEGY FOR BARRETT’S SURVEILLANCE: USINGCYTOSPONGE AND GASTROSCOPY OVER 14 MONTHS DURING COVID19
CHANGING STRATEGY FOR BARRETT’S SURVEILLANCE: USINGCYTOSPONGE AND GASTROSCOPY OVER 14 MONTHS DURING COVID19

Eosinophilic oesophagitis (Posters)  et al.

INHIBITORY EFFECT OF PHARMACOLOGICALLY-DERIVED OR ENDOGENOUSLY PRODUCED HYDROGEN SULFIDE (H2S) ON THE DEVELOPMENT OF BARRETT’S METAPLASIA THROUGH IL-1BETA/COX-2/PGE2 PATHWAY LOOP
INHIBITORY EFFECT OF PHARMACOLOGICALLY-DERIVED OR ENDOGENOUSLY PRODUCED HYDROGEN SULFIDE (H2S) ON THE DEVELOPMENT OF BARRETT’S METAPLASIA THROUGH IL-1BETA/COX-2/PGE2 PATHWAY LOOP

Eosinophilic oesophagitis (Posters)  et al.

DIFFERENCES IN TREATMENT PATTERNS AMONG PATIENTS DIAGNOSED WITH EOSINOPHILIC OESOPHAGITIS IN THE UNITED STATES
DIFFERENCES IN TREATMENT PATTERNS AMONG PATIENTS DIAGNOSED WITH EOSINOPHILIC OESOPHAGITIS IN THE UNITED STATES

Eosinophilic oesophagitis (Posters)  et al.

DUPILUMAB FOR THE TREATMENT OF EOSINOPHILIC ESOPHAGITIS: A MULTICENTER REAL-LIFE EXPERIENCE
DUPILUMAB FOR THE TREATMENT OF EOSINOPHILIC ESOPHAGITIS: A MULTICENTER REAL-LIFE EXPERIENCE

Eosinophilic oesophagitis (Posters)  et al.

NOVEL ROBUST METHOD FOR EOSINOPHIL COUNTING IN DUODENAL BIOPSY SECTIONS
NOVEL ROBUST METHOD FOR EOSINOPHIL COUNTING IN DUODENAL BIOPSY SECTIONS

Eosinophilic oesophagitis (Posters)  et al.

Item 1 - 18 / 18
1